AbbVie Inc.

NYSE:ABBV

Drug Manufacturers - General

Healthcare
$285.96 -2.10%

-$4.65 today

Market cap
$505.47B
Beta
0.31
P/E (TTM)
105.6
EPS (TTM)
$2.05
Dividend yield
3.11%
52W Low $181.73High $244.81

Volume 4.73M

Average 6.47M

ABBV Operating Cash Flow

Cash generated by the company's core business operations during the period.

AbbVie Inc.NYSE: ABBV

Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Operating cash flow dips below year-ago levels

Q2 FY2026 operating cash flow of $3.44B fell 33.3% year over year, behind the +1.2% change in trailing-twelve-month operating cash flow. Sequentially, it fell 10.3% from the prior quarter. Over 3 fiscal years it compounded at -8.6% a year.

Context

  • Operating cash flow amounted to 31.1% of revenue in FY2025, down 2.3 pp from a year earlier.
  • Operating cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -33.3% toward the trailing-twelve-month pace of +1.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.44B-10.3% QoQ
Last fiscal yearDec 2025
$19.03B+1.2% YoY
LTMJun 2026
$19.51B+1.2% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.3%——
1 year+1.2%——
3-year CAGR-8.6%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
19.03B USD
Year-over-year change
+1.2%
4-year CAGR
-4.4%

Operating Cash Flow vs competitors

How ABBV compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.2% is the 6th highest of 10, against a peer median of +3.9%.
  • Operating cash flow amounts to 30.3% of revenue for ABBV, versus a peer median of 26.3%.
ABBV Competitors
Operating Cash Flow for ABBV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$28.08B USD+156.7%+30.4%35.3%
JNJJohnson & JohnsonLTM Sep 2026$26.16B USD+8.1%+5.0%26.3%
MRKMerck & Co., Inc.LTM Jun 2026$19.97B USD+7.7%-4.8%30.1%
ABBVAbbVie Inc.LTM Jun 2026$19.51B USD+1.2%-8.6%30.3%
NVSNovartis AGLTM Jun 2026$18.39B USD-11.5%+10.6%33.1%
PFEPfizer Inc.LTM Jun 2026$13.4B USD-11.8%-26.3%21.0%
AZNAstraZeneca PLCLTM Sep 2026$13.33B USD-11.9%+14.1%21.4%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$12.78B USD-19.6%+2.7%26.0%
AMGNAmgen Inc.LTM Jun 2026$12.48B USD+3.9%+0.8%32.7%
GSKGSK plcLTM Jun 2026£8.74B GBP+13.2%-4.3%26.3%
Peer median (excluding ABBV) —+3.9%+2.7%26.3%

Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income11.55B11.85B4.82B4.29B4.23B
Depreciation & Amortization8.52B8.47B8.7B8.39B8.14B
Deferred Income Tax(898M)(1.93B)(2.89B)(1.45B)(492M)
Stock-Based Compensation692M671M747M911M955M
Change in Working Capital(1.32B)(258M)2.81B(2.78B)(2.36B)
Accounts Receivables(1.32B)(1.46B)66M207M(1.49B)
Inventory(142M)(686M)(417M)(319M)(234M)
Accounts Payables1.63B1.61B3.84B177M951M
Other Working Capital(1.49B)278M(676M)(2.85B)(1.59B)
Other Non-Cash Items4.24B6.15B8.65B9.45B8.6B
Operating Cash Flow22.78B24.94B22.84B18.81B19.03B
Capital Expenditures(787M)(695M)(777M)(974M)(1.21B)
Acquisitions (Net)(1.9B)(794M)(1.22B)(17.49B)(204M)
Purchases of Investments(119M)(1.44B)(77M)(73M)(35M)
Sales of Investments98M1.53B55M555M76M
Other Investing Activities366M774M13M(2.84B)(5.27B)
Investing Cash Flow(2.34B)(623M)(2.01B)(20.82B)(6.64B)
Debt Repayment(8.41B)(12.43B)(4.15B)7.35B(327M)
Common Stock Issued0000172M
Common Stock Repurchased(934M)(1.49B)(1.97B)(1.71B)(980M)
Dividends Paid(9.26B)(10.04B)(10.54B)(11.03B)(11.66B)
Other Financing Activities(430M)(840M)(562M)172M68M
Financing Cash Flow(19.04B)(24.8B)(17.22B)(5.21B)(12.72B)
Effect of Forex Changes(97M)(62M)5M(65M)42M
Net Change in Cash1.3B(545M)3.61B(7.29B)(295M)
Free Cash Flow21.99B24.25B22.06B17.83B17.82B

AbbVie Inc.

NYSE:ABBV

Intrinsic Alpha fair value

Locked

Current Price

$285.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.